These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 15071285

  • 21. Prevention of respiratory syncytial virus infection among Puerto Rican infants.
    Winchester L, García L, García I, Concepción CB.
    P R Health Sci J; 2002 Sep; 21(3):191-3. PubMed ID: 12243108
    [Abstract] [Full Text] [Related]

  • 22. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn.
    Pediatrics; 1998 Nov; 102(5):1211-6. PubMed ID: 9794957
    [Abstract] [Full Text] [Related]

  • 23. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
    Hampp C, Kauf TL, Saidi AS, Winterstein AG.
    Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
    [Abstract] [Full Text] [Related]

  • 24. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants.
    Singleton R, Dooley L, Bruden D, Raelson S, Butler JC.
    Pediatr Infect Dis J; 2003 Jun; 22(6):540-5. PubMed ID: 12799511
    [Abstract] [Full Text] [Related]

  • 25. Respiratory syncytial virus morbidity and outpatient palivizumab dosing in South Carolina, 2004-2009.
    Chadha AD, Bao W, Holloway J, Mann J, Rye AK, Brown DE.
    South Med J; 2012 Aug; 105(8):399-404. PubMed ID: 22864095
    [Abstract] [Full Text] [Related]

  • 26. Evaluation of a novel web-based prior approval application for palivizumab prophylaxis of respiratory syncytial virus in a state Medicaid program.
    Lundeen K, Pfeiffenberger T, Jacobson Vann J, O'Brien T, Sampson C, Wegner S.
    J Manag Care Pharm; 2013 Mar; 19(2):115-24. PubMed ID: 23461427
    [Abstract] [Full Text] [Related]

  • 27. Respiratory disorders and hospitalization rates during the second RSV season in preterm infants who received palivizumab prophylaxis during their first RSV season.
    Fanos V, Scarcella A, Puddu M, Gallini F, Tuminelli F, Bragetti P, Gallina MR, Quartulli L, Benincori N, Citro G, Via LD, Barera G, DI Luzio Paparatti U, Merolla R, Romano GV, Guida G, Silvestri M, Rossi GA.
    J Chemother; 2009 Jun; 21(3):302-10. PubMed ID: 19567351
    [Abstract] [Full Text] [Related]

  • 28. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain.
    Figueras-Aloy J, Carbonell-Estrany X, Quero J, IRIS Study Group.
    Pediatr Infect Dis J; 2004 Sep; 23(9):815-20. PubMed ID: 15361718
    [Abstract] [Full Text] [Related]

  • 29. Beyond randomized controlled trials: a "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab.
    Mitchell I, Tough S, Gillis L, Majaesic C.
    Pediatr Pulmonol; 2006 Dec; 41(12):1167-74. PubMed ID: 17058279
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?
    Geskey JM, Ceneviva GD, Brummel GL, Graff GR, Javier MC.
    Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group.
    Sáez-Llorens X, Castaño E, Null D, Steichen J, Sánchez PJ, Ramilo O, Top FH, Connor E.
    Pediatr Infect Dis J; 1998 Sep; 17(9):787-91. PubMed ID: 9779762
    [Abstract] [Full Text] [Related]

  • 38. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.
    Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA.
    Pediatrics; 1999 Sep; 104(3 Pt 1):419-27. PubMed ID: 10469764
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.